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WEB-2086 – an antagonist of platelet-activating factor receptor (PAFR) with known anti-inflammatory, antiangiogenic and
antileukaemic properties – also proved to inhibit the proliferation in human solid tumour cell lines of different histology, and with
much higher efficacy than in normal fibroblasts. A detailed analysis of WEB-2086 anticancer activity was then performed focusing on
breast adenocarcinoma MCF-7 and MDA-MB-231 cells. WEB-2086-treated cells, either expressing (MCF-7) or unexpressing (MDA-
MB-231) the oestrogen receptor (ER)a, underwent a dose-dependent growth arrest (IC50¼0.6570.09 and 0.4170.07mM,
respectively) and accumulation in G0–G1 phase. WEB-2086 also induced morphological and functional changes typical of mature
mammary phenotype including (i) cell enlargement and massive neutral lipid deposition (best accomplished in MCF-7 cells); (ii)
decrease in motility and active cathepsin D levels (mainly observed in highly invasive MDA-MB-231 cells). The expression of ERa was
neither increased nor reactivated in treated MCF-7 or MDA-MB-231 cells, respectively. WEB-2086-induced differentiation in breast
cancer cells involved the upregulation of PTEN, a key tumour suppressor protein opposing tumorigenesis, and was apparently
independent of p53, PAFR, peripheral benzodiazepine receptor and ERa status. Overall, WEB-2086 can be proposed as an effective
antiproliferative and differentiative agent with interesting translational opportunities to treat breast cancers in support to conventional
chemotherapy.
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Differentation-inducing therapy found its best clinical application
by using all-trans-retinoic acid (ATRA) (Warrell et al, 1991)
and STI571 (Druker, 2002) to cure successfully acute promyelo-
cytic leukaemia (APL) and chronic myelogenous leukaemia,
respectively. Such excellent effects, however, were not reproduced
in other haematological and, particularly, in solid tumours, which,
therefore, represent a real challenge for differentiative agents.
We showed previously that WEB-2086 – an antagonist of
platelet-activating factor receptor (PAFR) with known anti-
inflammatory properties (Ishii and Shimizu, 2000) – could also
induce erythroleukaemia cell maturation (Cellai et al, 2002),
enhance ATRA differentiation potential, trigger apoptosis in
ATRA-sensitive and -resistant APL cell lines, and in blasts from
patients with APL (Laurenzana et al, 2005). These results
prompted us to investigate WEB-2086 effects also in solid tumour
cells. We examined different cell lines from human breast
adenocarcinoma, colon adenocarcinoma, hepatocarcinoma, fibro-
sarcoma, and neuroblastoma and found that the drug induced
growth arrest in all types of cancer cells and with much higher
efficacy than in normal cells.
WEB-2086 activity was then systematically analysed in MCF-7
and MDA-MB-231 breast adenocarcinoma cell lines. MCF-7 are
low-migrating cells expressing oestrogen receptor (ER)a while
MDA-MB-231 are ERa-negative cells with high mobility and
invasive potential (Bussolati et al, 2000). These models have been
widely used to test in vitro differentiation activity of agents like
Na-butyrate and hexamethylene bisacetamide (HMBA) (Guilbaud
et al, 1990), and retinoids including ATRA (Wang et al, 2001).
More recently, emphasis was given to histone deacetylase
inhibitors (HDACi) such as suberoylanilide hydroxamic acid
(SAHA) and trichostatin A (TSA) which induce differentiation in
breast cancer cells in vitro (Yang et al, 2000; Munster et al, 2001;
Jang et al, 2004) by altering their transcriptional programs.
However, the clinical use of HADCi including valproic acid to treat
breast cancer is severely limited by the drug-mediated increase of
ERa expression and tissue sensitization to tumour promotion
activity of oestrogens (Akhmedkhanov et al, 2001; Graziani et al,
2003).
In this study we report that WEB-2086 exerted a broad cytostatic
effect in cell lines from solid tumours of different histology.
Moreover, with respect to particularly MCF-7 and MDA-MB-231
breast adenocarcinoma cells, WEB-2086 could re-establish cell
growth and migration control regardless of ERa status, and restore
also some traits of mature mammary phenotype without enhan-
cing and/or reactivating ERa expression. All these properties point
to WEB-2086 as a novel differentiation agent with a low-toxic
profile in vivo (Adamus et al, 1989) and with interesting
therapeutic potential for treating breast cancers in support to
conventional cytotoxics.
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sMATERIALS AND METHODS
Cells, culture conditions and reagents
Media used (Bio-Whittaker Europe, Verviers, Belgium) were
IMDM for MCF-7 and Hep-G2; DMEM for MDA-MB-231, HT-
1080 and dermal fibroblasts; RPMI for SH-SY5Y (plus 1% non-
essential AA) and HCT-8 (plus 1mM Na-pyruvate). Cells were
propagated in the presence of 10–15% foetal bovine serum (FBS,
EuroClone, Life Science Division, Milan, Italy) and 2mML -
glutamine at 371Ci n5 %C O 2 humidified atmosphere. Cells were
harvested with a trypsin-EDTA solution (Bio-Whittaker Europe),
plated (1.5 10
4ml
 1) and left for 6h before any treatment. WEB-
2086 (Casals-Stenzel et al, 1987) (Boehringer Ingelheim Pharma
KG, Biberach, Germany), was dissolved in dimethyl sulfoxide
(DMSO; Sigma-Aldrich, St Louis, MO, USA); the stock solution
(260mM) was stored in the dark at room temperature. HMBA, Na-
butyrate and ATRA were from Sigma-Aldrich; other chemicals
were reagent grade. Cells treated with increasing WEB-2086 for
72h were harvested and counted in a Bu ¨rker chamber to assess the
drug concentration necessary to reduce cell density by 50% as
compared to control (IC50 value).
Flow cytometry
Cell cycle distribution was determined by the propidium iodide
(PI)-hypotonic citrate method with a FACScan instrument
(Becton-Dickinson, San Jose, CA, USA) (Paoletti et al, 1996).
The number of cell replications was assessed with the aid of
carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular
Probes, Eugene, OR, USA), which covalently binds cell compo-
nents to yield a fluorescence that was divided equally between
daughter cells at each division (Lyons et al, 2001). Cells were
starved for 14h with the medium containing 0.5% FBS, then
harvested and labelled with CFSE following the manufacturer’s
instruction. Labelled cells (day 0) were used to measure initial
levels of fluorescence and then seeded (2 10
4cellsml
 1) with or
without either WEB-2086 (0.5–1.5mM) or DMSO as the vehicle
(0.19–0.57%) to calculate replication number after 5 days of
treatment (software: ModFit LT for Macintosh, Proliferation
Protocol, Verity Software House Inc., Topsham, ME, USA).
Cell morphology, apoptosis and neutral lipid
determination
Morphological changes were microscopically examined either by
phase contrast or ethanol-fixed cells stained with haematoxylin-
eosin using a Digital Camera System Leica DC 200 (Leica
Microsystems, Inc. Bannockburn, IL, USA). Apoptosis was
revealed by the presence of nuclear fragmentation in stained cells
and by the DNA ladder assay as reported previously (Laurenzana
et al, 2005).
Neutral lipids were determined (i) histochemically (Constanti-
nou et al, 1998) on cell monolayers which were quickly fixed with
 201C methanol, stained with Oil Red O (Sigma-Aldrich) and
counterstained with haematoxylin; or (ii) spectrophotometrically
(Cary 50 Scan, Varian, Victoria, Australia) at 510nm by recording
absorbance of cell-bound Oil Red O following extraction with
isopropanol (Wang et al, 2001).
Reverse transcription–polymerase chain reaction
Total RNA was prepared with TRIzol (Invitrogen, Carlsbad, CA,
USA), following the manufacturer’s instructions. Samples (1mg
each) were reverse-transcribed and then amplified by PCR with the
following primers. For ERa,5 0-CAAGCCCGCTCATGATCA-30 and
50-CACCATGCCCTCTACACA-30 (388bp); for peripheral benzo-
diazepine receptor (PBR), 50-CACGCTCTACTCAG-CCATGG-30
and 50-GCAGTAGTTGAGTGTGGTCGC-30 (298bp); for PAFR, 50-A
CCAACACAGTGCCCGACAGTGCT-30 and 50-GGGTGACCTGATG
TGCATCA-TTAAT-30 (363bp); for b2-microglobulin, 50-CTCGCG
CTACTCTCT-CTTTCT-30 and 50-ACATGGAGACAGCACTCAA
AG-30 (514bp). Reverse transcription-polymerase chain reaction
(RT–PCR) products were analysed as described previously (Cellai
et al, 2002).
Cell migration
Cell mobility was assessed in Boyden’s chambers using a
polyvinyl-pyrrolidone-free polycarbonate filter (8mm pore size)
between the two chambers (Alessandri et al, 1986). After a 6-h
incubation at 371C, cells (2.5 10
4, 0.2ml
 1) on the upper surface
of filters were scraped; filters, were then fixed in methanol, stained
with Wright-Giemsa and photographed as above.
SDS–PAGE and Western blotting
Harvested cells were resuspended in the lysis buffer (Laurenzana
et al, 2005) and separated on 12.5% SDS–PAGE. Western-blot
membranes were probed using primary antibodies against
cathepsin D, p53, PTEN, and a-tubulin (Santa Cruz Biotech, Santa
Cruz, CA, USA) and ERa (Ventana Medical Systems, Tucson, AZ,
USA). Peroxidase-conjugated secondary antibodies (Santa Cruz
Biotech) and the ECL procedure on Hyperfilm ECL (Amersham
Pharmacia Biotech) were used for development.
Statistical analysis
All experiments were independently done at least three times. All
data were statistically analysed by Student’s t-test.
RESULTS
WEB-2086 inhibited proliferation in six different solid
tumour cell lines
Human tumour cells from breast adenocarcinoma (MCF-7 and
MDA-MB-231), ileocecal adenocarcinoma (HCT-8), hepatocarci-
noma (Hep-G2), fibrosarcoma (HT-1080), and neuroblastoma
(SH-SY5Y) were cultured with increasing WEB-2086 concentra-
tions for 3 days. IC50 values of solid tumour cells were within the
range of 0.38–0.83mM WEB-2086 (mean value B0.61mM)
(Table 1). HT-1080 and HCT-8 were the more and the less drug-
responsive cells, respectively, while normal human fibroblasts used
as control yielded a mean IC50 value 44m M. These data indicated
that solid tumour cells, irrespective of their histogenesis, were all
especially sensitive to WEB-2086-induced cytostasis thus inferring
that a common pathway might be involved. WEB-2086 effects have
been then analysed further in breast adenocarcinoma cells: MCF-7
which are hypotetraploid, ERa-positive and low-mobility cells
expressing the wild-type p53 form; and MDA-MB-231 which are
Table 1 Inhibition of cell growth by WEB-2086: IC50 values in cell lines
from different human solid tumours and in control dermal fibroblasts
Cell lines IC50 (mM)
a
Breast adenocarcinoma (MCF-7) 0.6570.09
Breast adenocarcinoma (MDA-MB-231) 0.4170.07
Hepatocyte adenocarcinoma (Hep-G2) 0.7870.07
Colon adenocarcinoma (HCT-8) 0.8370.09
Fibrosarcoma (HT-1080) 0.3870.04
Neuroblastoma (SH-SY5Y) 0.6270.07
Dermal fibroblast (Control) 4.3070.21
aMeans values of four experiments.
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shypotriploid, ERa-negative and highly invasive cells carrying a
mutated and inactive p53 form.
WEB-2086 induced growth arrest and differentiation in
MCF-7 cells
WEB-2086-treated MCF-7 cells underwent a striking inhibition of
growth that was virtually abolished at X1m M drug (Figure 1A).
WEB-2086 effects on MCF-7 replicative potential was evaluated by
tracking subsequent rounds of cell division with the fluorescent
dye CFSE (see Materials and methods) after a 5-day incubation of
cultures with or without increasing WEB-2086 concentrations
(Figure 1B and legend). Approximately 75% of untreated MCF-7
cells approached the fourth generation and 23% reached the third
generation. Conversely, in MCF-7 cultures incubated with 1 or
1.5mM WEB-2086, the predominant fraction (67 and 92%,
respectively) was represented by cells arrested after two replica-
tions only.
Cytofluorimetric analysis of cell cycle (Figure 1C) showed that a
2-day treatment led to a dose-dependent MCF-7 accumulation in
G0–G1 phase to reach approximately 66 and 74% of population at
1 and 1.5mM drug, respectively. Concomitantly, there was a
decrease in G2-M/S cell fraction and a moderate increase in the
sub-G1 fraction over basal levels. However, DNA ladder assay and
morphology of treated cells indicated that apoptosis involved only
a minor portion of the population (data not shown).
MCF-7 incubated with 1mM WEB-2086 showed features that
were reminiscent of mature mammary phenotype including an
increase in cell size and eosinophilia, a reduced nuclear/
cytoplasmic ratio, and a shift from a round to columnar shape
to yield adenoma-like clusters where a central lumen was often
recognized (Figure 2 left, B vs A). Red Oil O staining of treated
MCF-7 cells revealed a massive accumulation of neutral lipids,
which are an important milk component and the most typical trait
of mature epithelial mammary cells (Figure 2 left, D and insert, vs
C).
Cell density and neutral lipid levels were determined in MCF-7
incubated with increasing amounts of either WEB-2086 or HMBA
given alone or in combination (Figure 2, right). WEB-2086 caused
a marked dose-dependent decrease in cell density and increase in
neutral lipid content of approximately twofold, fivefold and 22-fold
over control levels after a 7-day incubation with 0.5, 1 and 1.5mM
drug, respectively. HMBA was much less efficient than WEB-2086
in inhibiting cell growth and inducing neutral lipid accumulation.
However, the two inducers acted synergistically. The combinations
of 0.5mM WEB-2086 with either 1 or 3mM HMBA inhibited MCF-7
cell growth and increased neutral lipid levels with higher efficacy
than the two drugs alone. No synergy was observed between WEB-
2086 and either Na-butyrate or ATRA (data not shown).
Response of MDA-MB-231 cells to WEB-2086
ERa-negative MDA-MB-231 cells were approximately 40% more
sensitive than ERa-positive MCF-7 cells to drug-induced inhibition
of cell growth (Figure 3A and Table 1). Treated MDA-MB-231
turned into scanty elongated and moderately enlarged fibroblast-
like cells with no tendency to form bundles (Figure 3B). Cell cycle
analyses showed that approximately 56 and 70% of MDA-MB-231
treated for 2 days with 0.5 and 1mM WEB-2086, respectively, were
arrested in G0–G1 phase; concomitantly, the G2-M/S cell fraction
decreased while the sub-G1 fraction slightly increased (Figure 3C).
Neutral lipids were already detectable in untreated MDA-MB-
231 cells but increased markedly upon WEB-2086 addition
(Figure 3D) though at half the rate of MCF-7 cells.
WEB-2086 reduced breast cancer cell mobility and active
cathepsin D levels
MDA-MB-231, unlike MCF-7, are cells with high mobility and have
been used, therefore, to monitor WEB-2086 effects on cell
migration and cathepsin D levels which associate closely with
breast cancer invasiveness (Rochefort et al, 2000). Results of
Boyden’s chamber experiments (Figure 4A) showed that a 5-day
incubation of MDA-MB-231 with 0.5mM WEB-2086 decreased cell
migration of approximately 75% while the low-migrating activity
of MCF-7 was virtually unaffected by 1mM drug. Moreover, WEB-
2086 treatment of MDA-MB-231 decreased the active form of
cathepsin D (lower band) and increased its inactive precursor
protein (upper band) (Figure 4B); the latter was the only form
present in low-invasive MCF-7 cells, irrespective of treatment.
Molecular and biochemical changes induced by WEB-2086
on PBR, PAFR, ERa, PTEN and p53 in MCF-7 and
MDA-MB-231 cells
Drug effects on peripheral benzodiazepine receptor (PBR) mRNA
levels in MCF-7 and MDA-MB-231 cells have been analysed;
WEB-2086 was reported to bind these receptors (Svetlov et al,
1996) which are a hallmark of aggressive adenocarcinoma cells
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Figure 1 WEB-2086 effects on MCF-7 cells. (A) Cultures treated for 5
days with increasing (0–1.5mM) drug were monitored for changes in cell
density. (B) Cells were labelled with CFSE and immediately examined to be
used as the starting population (top panel, day 0, ). After a 5-day
incubation with 0–1.5mM WEB-2086, the generation numbers were
calculated (bottom panel) and indicated by the listed colours: first ( ),
second ( ), third ( ), fourth ( ), fifth ( ). (C) Flow cytometry profiles of
PI-stained MCF-7 cells incubated for 2 days with 0–1.5mM WEB-2086.
Percentages of cells in the different phases of cell cycle were reported.
Experiments carried out with DMSO as the vehicle (up to 0.57%) showed
negligible interference with cell growth, replication rounds and cell cycle
(data not shown).
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s(Hardwick et al, 2001). After a 5-day treatment, PBR expression
was downmodulated and, particularly, in highly invasive MDA-
MB-231 cells (Figure 5A). Instead, PAFR expression was unaffected
by the drug in both cell lines (data not shown).
The incubation of MCF-7 or MDA-MB-231 cells with WEB-2086
neither increased (actually, slightly decreased) nor restored ERa
protein levels, respectively (Figure 5B). Importantly, an increase in
PTEN protein relative to control was detected after a 2-day
incubation with WEB-2086 in MCF-7 and, especially, in MDA-MB-
231 cells (Figure 5C). Wild p53 levels in MCF-7 cells increased
early in response to WEB-2086 with a peak at 3h and then
decreased progressively with time; instead, high levels of mutated
p53 protein in MDA-MB-231 cells did not vary with treatment
(Figure 5D).
None 100 0.49 ± 0.04
0.5 mM WEB-2086 60.9 0.9 ± 0.09 
1 mM WEB-2086 13.4 2.54 ± 0.12 
1.5 mM WEB-2086 6.3 11.04 ± 0.9 
1 mM HMBA 93.3 0.59 ± 0.06
3 mM HMBA 53.9 0.63 ± 0.04 
0.5 mM WEB-2086 + 1 mM HMBA 20 2.5 ± 0.19
0.5 mM WEB-2086 + 3 mM HMBA 4.1 9.4 ± 0.6 
Addition Cell density Neutral lipidsa
(% Of control) (A510/106 cells)
AB
D C
Figure 2 Morphological and functional differentiation of MCF-7 by WEB-2086 and its synergy with HMBA. Left panel: Changes in morphology were
observed ( 40) following haematoxylin-eosin staining of cells grown onto glass-coverslips in the absence (A) or in the presence (B)o f1m M WEB-2086 for
5 days. Neutral lipids were revealed histochemically by Oil Red O staining of MCF-7 ( 10) incubated for 7 days without (C) or with 1mM WEB-2086 (D)
and insert ( 40). Magnification bars A–B¼25mm, C–D¼100mm. Right panel: Neutral lipid content (7s.d.) in cultures treated for 7 days with increasing
WEB-2086 (0–1.5mM) and/or HMBA (1–3mM) concentrations was determined by absorbance at A510/10
6 cells in isopropanol extracts of Oil Red
O-stained cells.
aSpectophotometric Assay (Wang et al, 2001).
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Figure 3 WEB-2086 effects on cell growth and differentiation of MDA-
MB-231 cells. (A) Cell density was monitored in cultures treated for 5 days
with increasing drug (0–1mM). (B) Morphological changes in MDA-MB-
231 untreated (control) or treated with 0.5mM WEB-2086 for 5 days
( 20); magnification bars¼50mm. (C) Flow cytometry profiles of PI-
stained MDA-MB-231 cells incubated for 2 days with WEB-2086 (0–
1m M); percentages of cells in different phases of cell cycle were reported.
(D) Top panel: Histochemistry of neutral lipids was performed by the Oil
Red O staining of MDA-MB-231 cultured for 14 days without (control) or
with 0.5mM WEB-2086 ( 10); bottom panel: spectrophotometric
evaluation of neutral lipid levels (7s.d.) in cultures incubated for 14 days
with increasing WEB-2086 as determined in Figure 2.
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Figure 4 WEB-2086-mediated effects on cell invasive potential. (A)
MDA-MB-231 and MCF-7 were previously incubated for 5 days without
(control) or with WEB-2086 (0.5 and 1mM, respectively) and then
transferred to the Boyden’s chamber for 6h. Cells on the lower side of the
filter were then stained and counted to determine migration activity;
magnification bars¼100mm. (B) Western-blot analysis of cathepsin D in
MDA-MB-231 and MCF-7 cells incubated for 5 days with 0.5 and 1mM of
WEB-2086, respectively; a-tubulin was used as the loading control.
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sDISCUSSION
Studies on WEB-2086 have primarily been performed with
leukaemia cells that were induced to differentiation and/or
apoptosis. Here we proved that WEB-2086 might exert a wider
anticancer activity being capable to decrease significantly pro-
liferation also in human solid tumour cells of different histogenesis
and with much higher efficacy than in normal cells. Then we
focused on breast adenocarcinoma cells lines and showed that
WEB-2086 can effectively inhibit in vitro cell growth and migration
as well as relieve the differentiation block in ERa-positive MCF-7
and ERa-negative MDA-MB-231 cells. WEB-2086-induced growth
arrest developed rapidly and led to a dose-dependent cell
accumulation in G0–G1 phase with only a moderate activation of
apoptosis. On a molar basis, differentiation efficacy of WEB-2086
was from 6- to 12-fold higher than that of butyrates and HMBA
(Guilbaud et al, 1990).
Drug-induced changes in morphology and neutral lipid
accumulation were more promptly elicited in ERa-positive MCF-
7 cells while the decrease in mobility and active cathepsin D levels
was especially observed in highly migrating ERa-negative MDA-
MB-231 cells. Importantly, WEB-2086 effects were reversed upon
drug removal to suggest that for potential therapeutic purposes
carcinoma cells should receive the drug continuously as reported
for other differentiation inducers such as butyrates (Guilbaud et al,
1990), TSA (Jang et al, 2004) and SAHA (Munster et al, 2001).
Moreover, specific HDACi including valproic acid increased and/
or reactivated ERa expression (Yang et al, 2000; Graziani et al,
2003) and sensitize both ERa-positive and ERa-negative breast
cancers to treatment with tamoxifen (Jang et al, 2004). However,
tamoxifen acts as an antioestrogen in breast, but as an oestrogen in
the uterus, bone and cardiovascular system (Sommer and Fuqua,
2001) and its administration was associated with endometrial
tumour development (Akhmedkhanov et al, 2001; Graziani et al,
2003). Noteworthy, WEB-2086 did neither increase nor restore ERa
expression in MCF-7 or MDA-MB-231 cells, respectively.
WEB-2086 action mechanisms in breast cancer cells are still
unclear but it is unfeasible that p53 could be involved as MDA-
MB-231 cells express a mutated and inactive protein form. Moreover,
the relatively high WEB-2086 amounts required to induce
adenocarcinoma cell cytostasis and differentiation seem to rule
out a relevant role of classical PBR and PAFR. This hypothesis is in
keeping with other studies reporting that ligands of PBR like
PK11195 and Ro 5-4864 (Carmel et al, 1999), and of PAFR such as
SDZ 62-434 (Brunton and Workman, 1993) and CV 3988 (Bussolati
et al, 2000) inhibited breast cancer cell proliferation at micromolar
levels which are not consistent with high-affinity ligand-receptor
binding. Importantly, WEB-2086 induced the upregulation of
PTEN protein in MCF-7 and, especially, in MDA-MB-231 cells.
PTEN plays a key role in several tumours including breast cancers
by contrasting the activation of proto-oncogenic phosphatydilino-
sitol 30 kinase (PI3K)-Akt signalling pathway and also tumorigen-
esis (Pandolfi, 2004; Chen et al, 2005). Increase in PTEN levels and
cell accumulation in G0–G1 phase as observed in treated breast
cancer cells might be part of a more general mechanism common
to other tumour cell types that, irrespective of their histology, were
all sensitive to WEB-2086-induced growth arrest.
Overall, we demonstrated that WEB-2086 (a) induced a dose-
dependent cytostasis in a panel of human cell lines from distinct
solid tumours; (b) promoted morphological and functional
differentiation in both ERa-positive MCF-7 and ERa-negative
MDA-MB-231 cells through, possibly, PTEN upmodulation; (c) did
not enhance/reactivate ERa expression; (d) synergized with
HMBA. Two final comments might emphasize further the
translational opportunities of WEB-2086. First, the drug proved
to be relatively safe in animal models and humans (Adamus et al,
1989) and produced negligible alterations of clinical parameters
when administered to thrombocytopenic patients (Lohmann et al,
1988; Giers et al, 1990). Second, WEB-2086 capability to abrogate
the PAF-mediated signal will contribute to reduce growth,
tumorigenic and metastatic potential of transformed cells, and
impact also cancer microenvironment by contrasting neoangio-
genesis (Bussolati et al, 2000).
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